Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) EBITDA Margin (2019 - 2025)

Biodesix's EBITDA Margin history spans 7 years, with the latest figure at 6.84% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 2571.0% year-over-year to 6.84%; the TTM value through Dec 2025 reached 31.5%, up 1687.0%, while the annual FY2025 figure was 31.5%, 1687.0% up from the prior year.
  • EBITDA Margin reached 6.84% in Q4 2025 per BDSX's latest filing, up from 32.39% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 6.84% in Q4 2025 to a low of 220.85% in Q1 2022.
  • Average EBITDA Margin over 5 years is 87.47%, with a median of 63.77% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: surged 14593bps in 2021, then crashed -20150bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 161.67% in 2021, then rose by 11bps to 144.58% in 2022, then soared by 68bps to 46.84% in 2023, then surged by 31bps to 32.55% in 2024, then skyrocketed by 79bps to 6.84% in 2025.
  • Per Business Quant, the three most recent readings for BDSX's EBITDA Margin are 6.84% (Q4 2025), 32.39% (Q3 2025), and 48.55% (Q2 2025).